TLPH
TalpheraยทNASDAQ
--
--(--)
--
--(--)
TLPH Profile
Talphera, Inc.
A specialty pharmaceutical company that develops therapies for acute post-operative pain and cancer breakthrough pain
1850 Gateway Drive, Suite 175, San Mateo, CA 94404
--
Talphera, Inc., was originally registered in Delaware as SuRX, Inc., on July 13, 2005. The company subsequently changed its name to AcelRx Pharmaceuticals, and the company changed its name from "AcelRx Pharmaceuticals, Inc." to "Talphera, Inc." on January 10, 2024. The Company is a specialty pharmaceutical company focused on the development and commercialization of therapies for medical monitoring settings, with current R&D efforts focused on the regional anticoagulant Niyad for the dialysis circuit and the possible development of LTX-608 for other indications.
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
